Trials / Completed
CompletedNCT00160589
LEADER (LEvocetirizine And DEsloratadine in Allergic Rhinitis)
A Multicentre, Double-blind, Parallel, Randomized, Placebo-controlled Study : Evaluation of the Efficacy and Safety of Levocetirizine 5 mg and Desloratadine 5 mg Administered Orally as Capsules Once Daily, in the Morning, Over 2 Weeks in Patients Suffering From Allergic Rhinitis (AR)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 729 (planned)
- Sponsor
- UCB Pharma · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- —
Summary
Two weeks study to evaluate the efficacy and safety of Levocetirizine and Desloratadine in patients suffering from Allergic Rhinitis (AR)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Levocetirizine |
Timeline
- Start date
- 2005-04-01
- Primary completion
- 2005-09-01
- Completion
- 2005-09-01
- First posted
- 2005-09-12
- Last updated
- 2013-12-16
Source: ClinicalTrials.gov record NCT00160589. Inclusion in this directory is not an endorsement.